Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Financing Activities (2020 - 2024)

Immuneering (IMRX) has 5 years of Cash from Financing Activities data on record, last reported at -$40988.0 in Q4 2024.

  • For Q4 2024, Cash from Financing Activities fell 623.14% year-over-year to -$40988.0; the TTM value through Dec 2024 reached $5.3 million, down 81.35%, while the annual FY2024 figure was $5.3 million, 81.35% down from the prior year.
  • Cash from Financing Activities reached -$40988.0 in Q4 2024 per IMRX's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $118.5 million in Q3 2021 and bottomed at -$184677.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $13.5 million, with a median of $110447.5 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: crashed 2556.14% in 2022, then surged 101297.86% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $37.0 million in 2020, then crashed by 99.98% to $7519.0 in 2021, then plummeted by 2556.14% to -$184677.0 in 2022, then skyrocketed by 104.24% to $7835.0 in 2023, then tumbled by 623.14% to -$40988.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$40988.0 in Q4 2024, $4.4 million in Q3 2024, and $979923.0 in Q1 2024.